Back to Search
Start Over
Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields
- Source :
- International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2008, 70 (3), pp.908-915. 〈10.1016/j.ijrobp.2007.10.034〉, International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2008, 70 (3), pp.908-915. ⟨10.1016/j.ijrobp.2007.10.034⟩
- Publication Year :
- 2008
- Publisher :
- HAL CCSD, 2008.
-
Abstract
- International audience; PURPOSE: After successful treatment of cancers in childhood, the occurrence of second malignant neoplasm (SMN) came to the fore. Few studies have considered the relationship between the radiation dose received and the risk of developing an SMN. To take into account the heterogeneity of the dose distribution so as to evaluate the overall risk of an SMN after a childhood cancer, we therefore focused on the integral dose restricted to the irradiated fields. METHODS AND MATERIALS: The study was performed in a cohort of 4,401 patients who were 3-year survivors of all types of childhood cancer treated between 1947 and 1986 in France and Great Britain. For each patient, the integral dose was estimated for the volume inside the beam edges. RESULTS: We found a significant dose-response relationship between the overall risk of an SMN and the estimated integral dose. The excess relative risk for each incremental unit of the integral dose was only 0.008 in a linear model and 0.017 when a negative exponential term was considered, when adjusted for chemotherapy. The risk of SMN occurrence was 2.6 times higher in the case of irradiation. However among patients who had received radiotherapy, only those who had received the highest integral dose actually had a higher risk. CONCLUSIONS: The integral dose in our study cannot be considered as a good predictor of later risks. However other studies with the same study design are obviously needed to evaluate the use of the integral dose as a tool for decision making concerning different radiotherapy techniques.
- Subjects :
- Oncology
Male
MESH: Neoplasms, Radiation-Induced
Neoplasms, Radiation-Induced
medicine.medical_treatment
MESH: Regression Analysis
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
Correlation
0302 clinical medicine
MESH : Child
MESH: Child
MESH : Regression Analysis
MESH : Hodgkin Disease
Medicine
MESH: Incidence
MESH : Neoplasms, Second Primary
Child
Radiation
MESH: Risk
Incidence
MESH : Infant
MESH: Bone Neoplasms
MESH: Infant
MESH : Incidence
3. Good health
MESH : Antineoplastic Agents
Integral dose
England
030220 oncology & carcinogenesis
Child, Preschool
Cohort
Regression Analysis
MESH : Dose-Response Relationship, Radiation
Cohort study
medicine.medical_specialty
MESH : Cohort Studies
Antineoplastic Agents
Bone Neoplasms
03 medical and health sciences
MESH : Adolescent
Humans
MESH : Bone Neoplasms
MESH: Adolescent
MESH: Humans
MESH: Child, Preschool
MESH : Humans
Infant
Dose-Response Relationship, Radiation
medicine.disease
MESH : Neoplasms
Radiation therapy
Relative risk
MESH: Antineoplastic Agents
MESH: Female
Cancer Research
MESH : Risk
MESH : Child, Preschool
030218 nuclear medicine & medical imaging
Cohort Studies
MESH: England
Neoplasms
MESH: Neoplasms
MESH : Female
Survivors
MESH: Radiotherapy Dosage
MESH: Cohort Studies
MESH : Neoplasms, Radiation-Induced
MESH: Survivors
MESH : England
MESH : Radiotherapy Dosage
MESH: Infant, Newborn
Neoplasms, Second Primary
Radiotherapy Dosage
Hodgkin Disease
MESH: Hodgkin Disease
MESH: Sarcoma, Ewing's
MESH : Sarcoma, Ewing's
Female
France
Risk
MESH: Neoplasms, Second Primary
Adolescent
MESH : Survivors
MESH : Male
[SDV.CAN]Life Sciences [q-bio]/Cancer
Sarcoma, Ewing
MESH : Infant, Newborn
Internal medicine
MESH: Dose-Response Relationship, Radiation
Radiology, Nuclear Medicine and imaging
MESH : France
Chemotherapy
business.industry
Infant, Newborn
Cancer
MESH: Male
MESH: France
business
Nuclear medicine
Subjects
Details
- Language :
- English
- ISSN :
- 03603016
- Database :
- OpenAIRE
- Journal :
- International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2008, 70 (3), pp.908-915. 〈10.1016/j.ijrobp.2007.10.034〉, International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2008, 70 (3), pp.908-915. ⟨10.1016/j.ijrobp.2007.10.034⟩
- Accession number :
- edsair.doi.dedup.....1da5b5661d3e0c58f56497642a4ed0b0
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2007.10.034〉